CRISPR Therapeutics 将来の成長

Future 基準チェック /26

CRISPR Therapeutics利益と収益がそれぞれ年間34.5%と54.3%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-9.5% 35.2%なると予測されています。

主要情報

34.5%

収益成長率

35.2%

EPS成長率

Biotechs 収益成長	37.3%
収益成長率	54.3%
将来の株主資本利益率	-9.5%
アナリストカバレッジ	Good
最終更新日	11 Nov 2024

今後の成長に関する最新情報

更新なし

Recent updates

業績と収益の成長予測

LSE:0VRQ - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	559	-262	-294	-269	16
12/31/2025	138	-446	-370	-347	26
12/31/2024	15	-431	-182	-149	25
9/30/2024	203	-240	-191	-189	N/A
6/30/2024	202	-266	-129	-122	N/A
3/31/2024	272	-217	-169	-159	N/A
12/31/2023	371	-154	-272	-260	N/A
9/30/2023	170	-354	-295	-278	N/A
6/30/2023	170	-416	-362	-343	N/A
3/31/2023	100	-524	-377	-352	N/A
12/31/2022	1	-650	-533	-496	N/A
9/30/2022	14	-681	-509	-468	N/A
6/30/2022	15	-633	-516	-445	N/A
3/31/2022	915	312	414	504	N/A
12/31/2021	915	378	457	539	N/A
9/30/2021	902	412	465	544	N/A
6/30/2021	902	447	502	549	N/A
3/31/2021	1	-392	-309	-287	N/A
12/31/2020	1	-349	-257	-238	N/A
9/30/2020	77	-211	-167	-154	N/A
6/30/2020	289	20	45	55	N/A
3/31/2020	289	46	40	48	N/A
12/31/2019	290	67	50	57	N/A
9/30/2019	213	-11	18	25	N/A
6/30/2019	1	-200	-133	-128	N/A
3/31/2019	2	-185	-121	-117	N/A
12/31/2018	3	-165	-99	-96	N/A
9/30/2018	35	-117	-85	-83	N/A
6/30/2018	37	-91	N/A	-79	N/A
3/31/2018	40	-75	N/A	-69	N/A
12/31/2017	41	-68	N/A	-70	N/A
9/30/2017	11	-51	N/A	-75	N/A
6/30/2017	10	-41	N/A	-71	N/A
3/31/2017	7	-36	N/A	-69	N/A
12/31/2016	5	-23	N/A	-53	N/A
9/30/2016	3	-53	N/A	33	N/A
6/30/2016	2	-44	N/A	40	N/A
3/31/2016	1	-31	N/A	51	N/A
12/31/2015	0	-26	N/A	59	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 0VRQ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0VRQ今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 0VRQ今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 0VRQの収益 ( 54.3% ) UK市場 ( 3.6% ) よりも速いペースで成長すると予測されています。

高い収益成長: 0VRQの収益 ( 54.3% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 0VRQ 3 年以内に赤字になると予測されています。

CRISPR Therapeutics 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Second quarter 2024 earnings released: US$1.49 loss per share (vs US$0.98 loss in 2Q 2023)

Insufficient new directors

CRISPR Therapeutics Announces Executive Changes

First quarter 2024 earnings released: US$1.43 loss per share (vs US$0.67 loss in 1Q 2023)

CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing in Vivo Gene Editing Approach

Now 22% undervalued after recent price drop

New minor risk - Shareholder dilution

CRISPR Therapeutics AG, Annual General Meeting, May 30, 2024

Full year 2023 earnings released: US$1.94 loss per share (vs US$8.36 loss in FY 2022)

New minor risk - Shareholder dilution

CRISPR Therapeutics AG has filed a Follow-on Equity Offering in the amount of $279.999863 million.

CRISPR Therapeutics Announces U.S. Food and Drug Administration (FDA) Approval of CASGEVY™ for the Treatment of Transfusion-Dependent Beta Thalassemia

CRISPR Therapeutics AG Announces Resignation of Phuong Khanh Morrow as Chief Medical Officer, Effective January 26, 2024

CRISPR Therapeutics AG and Vertex Pharmaceuticals Incorporated Announce Receipt of the First-Ever Approval of a CRISPR-Based Gene-editing Therapy in the United States

CRISPR Therapeutics Announces Updates to Immuno-Oncology Pipeline and Expansion into Autoimmune Disease

Third quarter 2023 earnings released: US$1.41 loss per share (vs US$2.24 loss in 3Q 2022)

New minor risk - Share price stability

CRISPR Therapeutics Announces Completion of FDA Advisory Committee Meeting for Exagamglogene Autotemcel (exa-cel) for Severe Sickle Cell Disease

CRISPR Therapeutics Announces Leadership Transition Effective September 15, 2023

Second quarter 2023 earnings released: US$0.98 loss per share (vs US$2.40 loss in 2Q 2022)

Now 23% undervalued after recent price drop

Insufficient new directors

New minor risk - Shareholder dilution

Vertex Pharmaceuticals Incorporated and Crispr Therapeutics Announces Positive Results from Pivotal Trials of Exa-Cel for Transfusion-Dependent Beta Thalassemia and Severe Sickle Cell Disease

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce FDA Accepts Biologics License Applications for Exagamglogene Autotemcel (Exa-Cel) for Severe Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

First quarter 2023 earnings released: US$0.67 loss per share (vs US$2.33 loss in 1Q 2022)

Now 20% undervalued

Full year 2022 earnings released: US$8.36 loss per share (vs US$4.97 profit in FY 2021)

CRISPR Therapeutics Appoints Alex Harding, M.D., M.B.A., as Head of Business Development, Effective January 5, 2023

CRISPR Therapeutics AG Provides Update on Its Ongoing Phase 1 Carbon(Tm) Trial of Ctx110(R)

Third quarter 2022 earnings released: US$2.24 loss per share (vs US$1.67 loss in 3Q 2021)

CRISPR Therapeutics Announces Executive Changes

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX130™ for the Treatment of Cutaneous T-Cell Lymphomas (CTCL)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Announce Global exa-cel Regulatory Submissions for Sickle Cell Disease and Beta Thalassemia in 2022

Second quarter 2022 earnings released: US$2.40 loss per share (vs US$10.01 profit in 2Q 2021)

Investor sentiment improved over the past week

CRISPR Therapeutics AG Elects Maria Fardis as Board Member

CRISPR Therapeutics Presents Positive Results from its Phase 1 COBALT™-LYM Trial of CTX130™ in Relapsed or Refractory T Cell Malignancies at the 2022 European Hematology Association (EHA) Congress

Investor sentiment improved over the past week

Investor sentiment improved over the past week

CRISPR Therapeutics AG Announces the Appointment of Phuong Khanh Morrow as Chief Medical Officer, Effective May 23, 2022

CRISPR Therapeutics Announces Oral Presentation of New Clinical Data on Anti-CD70 Allogeneic CAR-T Therapy CTX130™ for Patients with T-cell Lymphoma at the Annual European Hematology Association (EHA) 2022 Hybrid Congress

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.51 loss in 1Q 2021)

Now 22% undervalued after recent price drop

CRISPR Therapeutics Proposes Appointment of Maria Fardis to the Board of Directors

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D)

Investor sentiment deteriorated over the past week

CRISPR Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to CTX110™ for the Treatment of Relapsed or Refractory CD19+ B-cell Malignancies

Third quarter 2021 earnings released: US$1.67 loss per share (vs US$1.32 loss in 3Q 2020)

Second quarter 2021 earnings released: EPS US$10.01 (vs US$1.30 loss in 2Q 2020)

Vertex Pharmaceuticals Incorporated and CRISPR Therapeutics Presents New Data in 22 Patients with Greater Than 3 Months Follow-Up Post-Treatment with Investigational Crispr/Cas9 Gene-Editing Therapy

First quarter 2021 earnings released: US$1.51 loss per share (vs US$1.15 loss in 1Q 2020)

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘